Syndax Pharmaceuticals Inc. ((SNDX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Syndax Pharmaceuticals Inc. is conducting a clinical study titled ‘A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)’. The study aims to assess the efficacy and safety of axatilimab, a potential treatment for IPF, a chronic lung disease with limited treatment options.
The intervention being tested is axatilimab, an experimental drug administered via intravenous infusion every two weeks. It is designed to treat IPF by potentially reducing lung inflammation and fibrosis.
The study follows an interventional design with participants randomly assigned to receive either axatilimab or a placebo. It employs a parallel intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment assignments. The primary goal is treatment-focused.
The study began on December 11, 2023, with an estimated primary completion date yet to be announced. The last update was submitted on August 21, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This study update could influence Syndax Pharmaceuticals’ stock performance positively if axatilimab shows promise, as it addresses a significant unmet medical need. Investors should watch for further developments, especially in comparison to competitors in the IPF treatment space.
The study is ongoing, with more details available on the ClinicalTrials portal.